Richtlijnen en literatuur

Richtlijnen

Er is op dit moment geen richtlijn voor aCML.

Literatuur

1. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Review 2019;33:74-81
2. Gotlib J. How I treat atypical chronic myeloid leukemia. Blood 2017;129(7):838-45
3. Palomo L et al. Molecular landscape and clonal architecture of adult myelodysplastic/ myeloproliferative neoplasms. Blood 2020;136(16):1851-62
4. Arber DA et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-28
5. Khoury JD et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-19
6. Mughal TI et al. An International MDS/MPN working group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/ myeloproliferative neoplasms. Haematologica 2015;100(9):1117-30
7. Savona MR et al. An international consortium proposal of uniform response criteria for myelodysplastic/ myeloproliferative neoplasms (MDS/MPN) in adults. Blood 2015;125(12):1857-65
8. Dao KT et al. Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia. J Clin Oncol 2020;38(10):1006-18

Ga terug naar de aCML homepage of lees meer over aCML:

• Inleiding
• Diagnostiek
• Classificatie
• Risicoclassificatie
• Behandeling
• Respons criteria
• Beheer en wijzigingenhistorie

Ga terug naar de algemene homepage Behandelprotocollen.